Intra-Cellular Therapies (NASDAQ:ITCI) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.09, MarketWatch Earnings reports.
Shares of ITCI traded down $1.69 during trading hours on Friday, reaching $18.09. The company had a trading volume of 318,300 shares, compared to its average volume of 397,314. The company has a market capitalization of $1.01 billion, a PE ratio of -8.53 and a beta of 1.13. Intra-Cellular Therapies has a 12-month low of $14.30 and a 12-month high of $25.82.
Several analysts have recently commented on ITCI shares. Cantor Fitzgerald restated a “buy” rating and issued a $28.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, July 23rd. Canaccord Genuity set a $31.00 price target on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a report on Thursday, August 2nd. ValuEngine upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Friday, August 3rd. Royal Bank of Canada reiterated a “buy” rating and issued a $35.00 price target on shares of Intra-Cellular Therapies in a report on Friday, August 3rd. Finally, BidaskClub upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Friday, September 28th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $28.00.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by WKRB News and is owned by of WKRB News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2018/11/10/intra-cellular-therapies-itci-posts-quarterly-earnings-results-beats-expectations-by-0-09-eps.html.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.
Featured Article: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.